Article info
PDFClinical science
Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm
- Correspondence to Dr Gustav Stålhammar, Ophthalmic Pathology and Oncology Service, St. Erik Eye Hospital, Stockholm 112 30, Sweden; gustav.stalhammar{at}ki.se
Citation
Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm
Publication history
- Received October 22, 2018
- Revised February 8, 2019
- Accepted March 5, 2019
- First published March 25, 2019.
Online issue publication
June 25, 2020
Article Versions
- Previous version (25 June 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.